Under Dems’ Drug Pricing Plan, Dozens of New Meds Will Never Be Invented
Under Dems’ Drug Pricing Plan, Dozens of New Meds Will Never Be Invented The Congressional Budget Office just released an [...]
Finland Healthcare, Regulatory and Reimbursement Landscape Market Report
Finland Healthcare, Regulatory and Reimbursement Landscape Market Report Finland Healthcare, Regulatory and Reimbursement Landscape Market Report is an essential source [...]
How pharma can help the post-COVID recovery of European cancer care
The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes [...]
With approval for China’s 2nd CAR-T therapy, Juno, WuXi joint venture goes up against Gilead and Fosun’s Yescarta
With approval for China's 2nd CAR-T therapy, Juno, WuXi joint venture goes up against Gilead and Fosun's Yescarta aliu Fri, [...]
Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines
Abstract Background Oncologists who author clinical practice guidelines frequently have financial relationships with the pharmaceutical industry. It is unknown whether [...]
House Democrats ramp up probe of FDA approval of Alzheimer’s drug – NewsBreak
Democratic leaders of two House committees are stepping up a probe of the Food and Drug Administration's (FDA) controversial approval [...]
New gene therapies may soon treat dozens of rare diseases, but price tags will put them out of reach for many – Japan Today
New gene therapies may soon treat dozens of rare diseases, but price tags will put them out of reach for [...]
Implementing More Effective FAIR Scientific Data Management With a Lakehouse
Data powers scientific discovery and innovation. But data is only as good as its data management strategy, the key factor [...]
HealthEconomics.Com Releases 2021 Insight Survey on Evidence-Based Healthcare
SAN DIEGO--(BUSINESS WIRE)--Sep 7, 2021-- HealthEconomics.Com , the world’s largest digital Connected Community™ for health economics and outcomes research (HEOR), [...]
Influential Usage of Big Data and Artificial Intelligence in Healthcare
Artificial intelligence (AI) is making computer systems capable of executing human brain tasks in many fields in all aspects of [...]
HealthEconomics.Com Announces Results of 2021 Insight Survey on Value Communication
HealthEconomics.Com, a Scientist.com company, reported the findings of its 2021 Insight Survey on Value Communication in Pharma HEOR, RWE & [...]
Reducing Healthcare Costs: What Questions Should We Be Asking
Let’s talk about leveraging data to drive analysis for pharma manufacturers. In this episode of Outcomes Rocket Pharma, we are [...]
Real-World Data Flow – The Only Way to Change Value-Based Care?
Healthcare interoperability issues have always been confusing, changing, and difficult to address. The reason why is not straightforward: we have [...]
Will Price Controls Limit Drug Development? The Debate Heats Up.
Legislative proposals for curbing outlays on prescription drugs have moved to center stage, as Congress looks hard for ways to [...]
The Pandemic Is Changing How We Value Health Care | Opinion
The COVID-19 pandemic upended the U.S. health care system, putting enormous strain on providers and hospitals, and discouraged patients from [...]
Democrats’ Success in Drug Pricing Legislation Hinges on Select Group of Individuals
Democrats are attempting to lower drug prices through legislation. Ten individuals could determine the initiative’s outcome. “The effort’s success depends [...]
Drug Pricing App GoodRx Announces Revenue of $177 Million in Second Quarter of 2021
GoodRx has announced a 43% revenue increase in its second quarter, leading to $177 million in revenue. Its subscribers hit [...]
Biogen Tempts Alzheimer’s Patients with Free Aduhelm; Will Ploy Lead to Medicare Coverage of $56,000 Yearly Drug?
In a recent podcast offered by the American Academy of Neurology, Dr. Brian Callaghan shares his thoughts on the cost-effectiveness of [...]
Congressional Budget Office’s Updated Model Predicts Impact of Pricing Legislation on Pharma Innovation
The Congressional Budget Office (CBO) released an updated model intended to predict how drug pricing bills, including Medicare negotiation, would [...]
HEOR Policy Experts Present Drug Pricing Reform Options, Discuss FDA’s Accelerated Approval Mechanism and Pricing Negotiation
Health economics and outcomes research (HEOR) experts at the USC-Brookings Schaeffer Initiative for Health Policy and the Washington University School [...]
New JMCP Article on International Reference Pricing Assesses Global Models
Drs. Leah Rand and Aaron Kesselheim recently published an article in the Journal of Managed Care and Specialty Pharmacy (JMCP) [...]
Indegene Announces Acquisition of Medical Marketing Economics Group in $10 Million Deal
Indegene, a technology-powered healthcare solutions company, announced the acquisition of Medical Marketing Economics (MME) in a $10 million deal. MME [...]
ICER’s RWE Study of Hereditary Angioedema Treatments Provides New Insight
The Institute for Clinical and Economic Review (ICER) recently published results from a real world evidence study (RWE) assessing the [...]
Economists and Policy Experts Discuss Six Strategies to Address High Drug Costs
Paul Ginsberg and Steven Lieberman of the USC-Brookings Schaeffer Initiative for Health Policy discuss six policies that could address the [...]
Can the FDA’s Humorous Social Media Posts Combat Scientific Misinformation?
The Food and Drug Administration (FDA) is incorporating humor into its social media messages aimed at reducing the spread of [...]